{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:43:15Z","timestamp":1791297795655,"version":"4.1.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T00:00:00Z","timestamp":1348185600000},"content-version":"vor","delay-in-days":570,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.jhep.2010.10.014","type":"journal-article","created":{"date-parts":[[2010,11,12]],"date-time":"2010-11-12T10:47:09Z","timestamp":1289558829000},"page":"566-576","source":"Crossref","is-referenced-by-count":175,"title":["Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies"],"prefix":"10.1016","volume":"54","author":[{"given":"Mirjam B.","family":"Zeisel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Fofana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Fafi-Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2010.10.014_b0005","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2010.10.014_b0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrgastro.2009.92","article-title":"New and experimental therapies for HCV","volume":"6","author":"Pereira","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2010.10.014_b0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.10.014_b0020","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature04083","article-title":"Hepatitis C and liver transplantation","volume":"436","author":"Brown","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2010.10.014_b0025","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bpg.2008.12.004","article-title":"Liver transplantation in viral hepatitis: prevention of recurrence","volume":"22","author":"Roche","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2010.10.014_b0030","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1073\/pnas.93.5.1759","article-title":"A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells","volume":"93","author":"Rosa","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2010.10.014_b0035","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1128\/JVI.72.5.3827-3836.1998","article-title":"Hepatitis C virus structural proteins assemble into virus-like particles in insect cells","volume":"72","author":"Baumert","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1\u2013E2 envelope protein complexes","volume":"197","author":"Bartosch","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2010.10.014_b0045","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1073\/pnas.0832180100","article-title":"Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles","volume":"100","author":"Hsu","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2010.10.014_b0050","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2010.10.014_b0055","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jhep.2010.10.014_b0060","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2010.10.014_b0065","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice with chimeric human livers","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2010.10.014_b0070","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1172\/JCI40094","article-title":"Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment","volume":"120","author":"Bissig","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2010.10.014_b0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhep.2008.03.012","article-title":"Mouse models for the study of HCV infection and virus\u2013host interactions","volume":"49","author":"Barth","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.10.014_b0080","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.23138","article-title":"Experimental models for hepatitis C viral infection","volume":"50","author":"Boonstra","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0085","doi-asserted-by":"crossref","first-page":"10159","DOI":"10.1128\/JVI.01180-10","article-title":"Characterization of the envelope glycoproteins associated with infectious hepatitis C virus","volume":"84","author":"Vieyres","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0090","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/JVI.02198-06","article-title":"Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry","volume":"81","author":"Ciczora","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0095","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins","volume":"79","author":"Goffard","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0100","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein","volume":"81","author":"Helle","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0105","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1073\/pnas.96.22.12766","article-title":"Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor","volume":"96","author":"Agnello","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2010.10.014_b0110","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/JVI.67.4.1953-1958.1993","article-title":"Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes","volume":"67","author":"Hijikata","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00198849","article-title":"Association of hepatitis C virus in human sera with beta-lipoprotein","volume":"181","author":"Thomssen","year":"1992","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jhep.2010.10.014_b0120","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/JVI.80.5.2418-2428.2006","article-title":"Association between hepatitis C virus and very-low-density lipoprotein (VLDL)\/LDL analyzed in iodixanol density gradients","volume":"80","author":"Nielsen","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0125","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/JVI.80.4.1817-1825.2006","article-title":"Functional analysis of hepatitis C virus envelope proteins, using a cell\u2013cell fusion assay","volume":"80","author":"Kobayashi","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0130","doi-asserted-by":"crossref","first-page":"8752","DOI":"10.1128\/JVI.02642-06","article-title":"Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus","volume":"81","author":"Lavillette","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0135","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1074\/jbc.M305289200","article-title":"Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor","volume":"278","author":"Bartosch","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0140","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1128\/JVI.02200-09","article-title":"Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes","volume":"84","author":"Bankwitz","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0145","first-page":"1","article-title":"Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies","volume":"317","author":"Keck","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jhep.2010.10.014_b0150","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","author":"Keck","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2010.10.014_b0160","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1128\/JVI.76.15.7672-7682.2002","article-title":"Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles","volume":"76","author":"Clayton","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0165","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1099\/0022-1317-82-8-1877","article-title":"Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2","volume":"82","author":"Owsianka","year":"2001","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0170","doi-asserted-by":"crossref","first-page":"10579","DOI":"10.1128\/JVI.00941-06","article-title":"Viral and cellular determinants of the hepatitis C virus envelope\u2013heparan sulfate interaction","volume":"80","author":"Barth","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0175","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1128\/JVI.00248-09","article-title":"Mutations in HCV E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity","volume":"83","author":"Keck","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0180","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2010.10.014_b0185","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1053\/j.gastro.2009.02.080","article-title":"Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus","volume":"136","author":"Dowd","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.10.014_b0190","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection","volume":"79","author":"Lavillette","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0195","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.10.014_b0200","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1128\/JVI.02265-09","article-title":"Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection","volume":"84","author":"Liu","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/hep.22307","article-title":"Host neutralizing responses and pathogenesis of hepatitis C virus infection","volume":"48","author":"Zeisel","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0210","doi-asserted-by":"crossref","first-page":"e1000143","DOI":"10.1371\/journal.ppat.1000143","article-title":"Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness","volume":"4","author":"Uebelhoer","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2010.10.014_b0215","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1084\/jem.20090766","article-title":"Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation","volume":"207","author":"Fafi-Kremer","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2010.10.014_b0220","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jhep.2010.10.014_b0225","doi-asserted-by":"crossref","first-page":"41003","DOI":"10.1074\/jbc.M302267200","article-title":"Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate","volume":"278","author":"Barth","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0230","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus","volume":"21","author":"Scarselli","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.jhep.2010.10.014_b0235","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1128\/JVI.77.7.4070-4080.2003","article-title":"Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR","volume":"77","author":"Pohlmann","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0240","doi-asserted-by":"crossref","first-page":"32035","DOI":"10.1074\/jbc.M402296200","article-title":"C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles","volume":"279","author":"Lozach","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0245","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature05654","article-title":"Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry","volume":"446","author":"Evans","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2010.10.014_b0250","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nature07684","article-title":"Human occludin is a hepatitis C virus entry factor required for infection of mouse cells","volume":"457","author":"Ploss","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2010.10.014_b0255","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/JVI.01888-08","article-title":"Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection","volume":"83","author":"Liu","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0260","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1074\/jbc.M709824200","article-title":"Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus","volume":"283","author":"Yang","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0265","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nri1182","article-title":"DC-SIGN: escape mechanism for pathogens","volume":"3","author":"van Kooyk","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2010.10.014_b0270","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1073\/pnas.0831128100","article-title":"L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus","volume":"100","author":"Gardner","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2010.10.014_b0275","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1128\/JVI.02460-05","article-title":"Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses","volume":"80","author":"Koutsoudakis","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0280","doi-asserted-by":"crossref","first-page":"8496","DOI":"10.1128\/JVI.78.16.8496-8505.2004","article-title":"Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner","volume":"78","author":"McKeating","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0285","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/hep.20542","article-title":"Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus","volume":"41","author":"Lavillette","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0290","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.78.3.1448-1455.2004","article-title":"CD81 is required for hepatitis C virus glycoprotein-mediated viral infection","volume":"78","author":"Zhang","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0295","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1128\/JVI.73.8.6235-6244.1999","article-title":"Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor CD81","volume":"73","author":"Flint","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0300","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1099\/0022-1317-81-12-2873","article-title":"Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding","volume":"81","author":"Patel","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0305","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1128\/JVI.80.10.4940-4948.2006","article-title":"Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry","volume":"80","author":"Bertaux","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0310","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1128\/JVI.00271-06","article-title":"Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding","volume":"80","author":"Owsianka","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0315","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1128\/JVI.02153-09","article-title":"Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus\u2013receptor interactions and sensitivity to neutralizing antibodies","volume":"84","author":"Dhillon","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0320","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1172\/JCI14011","article-title":"Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems","volume":"108","author":"Krieger","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2010.10.014_b0325","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1128\/JVI.02199-08","article-title":"Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants","volume":"84","author":"Catanese","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0330","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/hep.21994","article-title":"Scavenger receptor BI is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81","volume":"46","author":"Zeisel","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0335","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1128\/JVI.79.13.8217-8229.2005","article-title":"An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies","volume":"79","author":"Bartosch","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0340","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1074\/jbc.M411600200","article-title":"High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I","volume":"280","author":"Voisset","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0345","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.21139","article-title":"Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells","volume":"43","author":"von Hahn","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0350","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2006.09.024","article-title":"The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus","volume":"46","author":"Molina","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.10.014_b0355","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1096\/fj.05-4728fje","article-title":"The interaction of natural hepatitis C virus with human scavenger receptor SR-BI\/Cla1 is mediated by ApoB-containing lipoproteins","volume":"20","author":"Maillard","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2010.10.014_b0360","doi-asserted-by":"crossref","first-page":"e1000310","DOI":"10.1371\/journal.ppat.1000310","article-title":"Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains","volume":"5","author":"Dreux","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2010.10.014_b0365","doi-asserted-by":"crossref","first-page":"12465","DOI":"10.1128\/JVI.01457-07","article-title":"Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus","volume":"81","author":"Zheng","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0370","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1128\/JVI.01977-07","article-title":"The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus","volume":"82","author":"Meertens","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0375","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1083\/jcb.141.7.1539","article-title":"Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin","volume":"141","author":"Furuse","year":"1998","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jhep.2010.10.014_b0380","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22028","article-title":"Hepatitis C virus receptor expression in normal and diseased liver tissue","volume":"47","author":"Reynolds","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0385","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.02262-08","article-title":"Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell\u2013cell contacts","volume":"83","author":"Cukierman","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0390","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.23445","article-title":"Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2\u2013CD81\u2013claudin-1 associations","volume":"51","author":"Krieger","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0395","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/JVI.02286-07","article-title":"CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry","volume":"82","author":"Harris","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0400","doi-asserted-by":"crossref","first-page":"21092","DOI":"10.1074\/jbc.M110.104836","article-title":"Claudin association with CD81 defines hepatitis C virus entry","volume":"285","author":"Harris","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0405","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1128\/JVI.00038-09","article-title":"The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection","volume":"83","author":"Benedicto","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0410","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1053\/j.gastro.2010.02.004","article-title":"Glucocorticosteroids increase cell entry by hepatitis C virus","volume":"138","author":"Ciesek","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.10.014_b0415","doi-asserted-by":"crossref","first-page":"10055","DOI":"10.1128\/JVI.74.21.10055-10062.2000","article-title":"Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor","volume":"74","author":"Wunschmann","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0420","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1128\/JVI.02478-07","article-title":"Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells","volume":"82","author":"Barth","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0425","doi-asserted-by":"crossref","first-page":"12407","DOI":"10.1128\/JVI.01552-09","article-title":"Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization","volume":"83","author":"Schwarz","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0430","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1128\/JVI.00024-06","article-title":"Hepatitis C virus entry depends on clathrin-mediated endocytosis","volume":"80","author":"Blanchard","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0435","doi-asserted-by":"crossref","first-page":"11571","DOI":"10.1128\/JVI.01717-06","article-title":"Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles","volume":"80","author":"Meertens","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0440","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1099\/vir.0.81710-0","article-title":"Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis","volume":"87","author":"Codran","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0445","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1096\/fj.09-131920","article-title":"Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening","volume":"23","author":"Trotard","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2010.10.014_b0450","doi-asserted-by":"crossref","first-page":"e1000702","DOI":"10.1371\/journal.ppat.1000702","article-title":"RNA interference and single particle tracking analysis of hepatitis C virus endocytosis","volume":"5","author":"Coller","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2010.10.014_b0455","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1128\/JVI.00592-08","article-title":"Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity","volume":"82","author":"Farquhar","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0460","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1128\/JVI.00246-09","article-title":"Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells","volume":"83","author":"Mee","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0465","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2006.02.007","article-title":"Virus entry: open sesame","volume":"124","author":"Marsh","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2010.10.014_b0470","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.1094823","article-title":"How viruses enter animal cells","volume":"304","author":"Smith","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jhep.2010.10.014_b0475","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.20032","article-title":"Structural biology of hepatitis C virus","volume":"39","author":"Penin","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0480","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K","article-title":"A model for the hepatitis C virus envelope glycoprotein E2","volume":"40","author":"Yagnik","year":"2000","journal-title":"Proteins"},{"key":"10.1016\/j.jhep.2010.10.014_b0485","first-page":"133","article-title":"The entry machinery of flaviviruses","author":"Heinz","year":"2004","journal-title":"Arch Virol Suppl"},{"key":"10.1016\/j.jhep.2010.10.014_b0490","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.biolcel.2004.03.008","article-title":"Functional hepatitis C virus envelope glycoproteins","volume":"96","author":"Voisset","year":"2004","journal-title":"Biol Cell"},{"key":"10.1016\/j.jhep.2010.10.014_b0495","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1074\/jbc.M509747200","article-title":"Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes","volume":"281","author":"Lavillette","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0500","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/JVI.80.4.1734-1741.2006","article-title":"Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry","volume":"80","author":"Tscherne","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0505","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1053\/j.gastro.2008.07.018","article-title":"Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion","volume":"135","author":"Haberstroh","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.10.014_b0510","doi-asserted-by":"crossref","first-page":"17657","DOI":"10.1074\/jbc.M109.014647","article-title":"Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles","volume":"284","author":"Haid","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0515","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.21959","article-title":"Hepatitis C virus cell\u2013cell transmission in hepatoma cells in the presence of neutralizing antibodies","volume":"47","author":"Timpe","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0520","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1099\/vir.0.006700-0","article-title":"CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells","volume":"90","author":"Witteveldt","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0525","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2010.10.014_b0530","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.2741\/3450","article-title":"Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy","volume":"14","author":"Zeisel","year":"2009","journal-title":"Front Biosci"},{"key":"10.1016\/j.jhep.2010.10.014_b0535","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.biotechadv.2009.08.004","article-title":"RNAi as a new therapeutic strategy against HCV","volume":"28","author":"Khaliq","year":"2010","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.jhep.2010.10.014_b0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/095632020701800101","article-title":"Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?","volume":"18","author":"Balzarini","year":"2007","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.jhep.2010.10.014_b0545","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/AAC.41.7.1521","article-title":"Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development","volume":"41","author":"Boyd","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2010.10.014_b0550","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.47.8.2518-2525.2003","article-title":"Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin","volume":"47","author":"O\u2019Keefe","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2010.10.014_b0555","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0022-3565(24)29588-4","article-title":"Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins","volume":"297","author":"Shenoy","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2010.10.014_b0560","doi-asserted-by":"crossref","first-page":"25177","DOI":"10.1074\/jbc.M602431200","article-title":"Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans","volume":"281","author":"Helle","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0565","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2010.10.014_b0570","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1073\/pnas.0402253101","article-title":"CD81 is an entry coreceptor for hepatitis C virus","volume":"101","author":"Cormier","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2010.10.014_b0575","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2005.08.006","article-title":"Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses","volume":"69","author":"Lee","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2010.10.014_b0580","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1073\/pnas.0700760104","article-title":"Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins","volume":"104","author":"Huang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2010.10.014_b0585","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/JVI.02053-07","article-title":"Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion","volume":"82","author":"Gastaminza","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0590","doi-asserted-by":"crossref","first-page":"13783","DOI":"10.1128\/JVI.01091-07","article-title":"Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture","volume":"81","author":"Chang","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0595","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.23278","article-title":"Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles","volume":"51","author":"Benga","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0600","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.3748\/wjg.v13.i36.4824","article-title":"Neutralizing antibodies in hepatitis C virus infection","volume":"13","author":"Zeisel","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.10.014_b0605","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1006\/viro.1995.1196","article-title":"Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment","volume":"208","author":"Zibert","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2010.10.014_b0610","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/hep.22244","article-title":"Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain","volume":"47","author":"Vanwolleghem","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0615","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/JVI.01986-07","article-title":"Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein","volume":"82","author":"Perotti","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0620","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1073\/pnas.0705522104","article-title":"Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus","volume":"104","author":"Johansson","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2010.10.014_b0625","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/JVI.01872-07","article-title":"Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus","volume":"82","author":"Meunier","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0630","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0042-6822(03)00406-9","article-title":"Small molecule inhibition of hepatitis C virus E2 binding to CD81","volume":"314","author":"VanCompernolle","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2010.10.014_b0635","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.22547","article-title":"Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo","volume":"48","author":"Meuleman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0640","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1074\/jbc.M405009200","article-title":"Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1\/2 and p38 mitogen-activated protein kinases","volume":"280","author":"Baranova","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0645","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1074\/jbc.M411555200","article-title":"Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake","volume":"280","author":"Cai","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0650","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/hep.21406","article-title":"Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system","volume":"44","author":"Lavie","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0655","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.1128\/JVI.00193-07","article-title":"High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein","volume":"81","author":"Catanese","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0660","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2010.06.024","article-title":"Small molecule scavenger receptor bi antagonists are potent HCV entry inhibitors","volume":"54","author":"Syder","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.10.014_b0665","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1053\/j.gastro.2010.05.073","article-title":"Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes","volume":"39","author":"Fofana","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.10.014_b0670","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/AAC.50.4.1393-1401.2006","article-title":"Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation","volume":"50","author":"Vaillant","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2010.10.014_b0675","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.gastro.2009.04.048","article-title":"Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry","volume":"137","author":"Matsumura","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.10.014_b0680","first-page":"139","article-title":"Enfuvirtide, the first fusion inhibitor to treat HIV infection","volume":"7","author":"Poveda","year":"2005","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jhep.2010.10.014_b0685","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: a broad-spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jhep.2010.10.014_b0690","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1743-422X-3-56","article-title":"Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection","volume":"3","author":"Boriskin","year":"2006","journal-title":"Virol J"},{"key":"10.1016\/j.jhep.2010.10.014_b0695","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1053\/j.gastro.2007.02.038","article-title":"Inhibition of T-cell inflammatory cytokines, hepatocyte NF-\u03baB signaling, and HCV infection by standardized silymarin","volume":"132","author":"Polyak","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.10.014_b0700","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/hep.23587","article-title":"Multiple effects of silymarin on the hepatitis C virus lifecycle","volume":"51","author":"Wagoner","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.10.014_b0705","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/fvl.10.14","article-title":"Tight junctions and viral entry","volume":"5","author":"Zeisel","year":"2010","journal-title":"Future Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0710","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/lt.20405","article-title":"A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients","volume":"11","author":"Davis","year":"2005","journal-title":"Liver transpl"},{"key":"10.1016\/j.jhep.2010.10.014_b0715","first-page":"892","article-title":"HepeX-C (XTL Biopharmaceuticals)","volume":"5","author":"Borgia","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2010.10.014_b0720","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/lt.20876","article-title":"Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study","volume":"12","author":"Schiano","year":"2006","journal-title":"Liver transpl"},{"key":"10.1016\/j.jhep.2010.10.014_b0725","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/JVI.80.6.2654-2664.2006","article-title":"Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients","volume":"80","author":"Eren","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0730","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0735","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0740","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.1128\/JVI.01569-08","article-title":"Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies","volume":"82","author":"Grove","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0745","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1128\/JVI.01138-09","article-title":"Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus","volume":"83","author":"Broering","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2010.10.014_b0750","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2009.02.087","article-title":"Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin","volume":"137","author":"Biermer","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827810009815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827810009815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T20:13:09Z","timestamp":1740687189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827810009815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":150,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0168827810009815"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2010.10.014","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}